Home » Clinical Trials » Inherited retinal dystrophy » NCT05417126
NCT05417126

A Phase 2a, Open Label Multicenter Clinical Trial to Evaluate the Safety and Effects of a Single Intravitreal Injection of vMCO-010 Optogenetic Therapy in Subjects With Stargardt Disease

Study Summary

The purpose of the study is to evaluate the safety and effects of a single intravitreal injection of virally-carried Multi-Characteristic Opsin (vMCO-010) in Subjects with Stargardt Disease

Want to learn more about this trial?

Request More Info

Interventions

Gene Therapy-vMCO-010BIOLOGICAL
The vMCO-010 is an adeno-associated virus serotype 2-based vector carried multi-characteristic opsin (MCO) gene expression cassette

Study Locations

FacilityCityStateCountry
Nanoscope Clinical SiteMiamiFloridaUnited States
Nanoscope Clinical SiteMcAllenTexasUnited States

Official Trial Information

View on ClinicalTrials.gov

Data sourced from ClinicalTrials.gov. Last updated: April 14, 2026